A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer.
about
A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activityAn intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI)Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levelsYin Yang 1 regulates the transcriptional repression of SurvivinErbB2 and NFκB overexpression as predictors of chemoradiation resistance and putative targets to overcome resistance in muscle-invasive bladder cancer.Survivin is a therapeutic target in Merkel cell carcinoma.Prognostic and clinicopathological significance of survivin in colorectal cancer: a meta-analysisPreclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1.YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells.MicroRNA regulation and therapeutic targeting of survivin in cancer.Inhibition of survivin influences the biological activities of canine histiocytic sarcoma cell lines.Response of Merkel cell polyomavirus-positive merkel cell carcinoma xenografts to a survivin inhibitor.Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastomaResponse of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation.Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia.Emerging targeted therapies for castration-resistant prostate cancer.Inhibition of Survivin with YM155 Induces Durable Tumor Response in Anaplastic Thyroid Cancer.Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter.Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AMLUse of a Novel Integrase-Deficient Lentivirus for Targeted Anti-Cancer Therapy With Survivin Promoter-Driven Diphtheria Toxin ADual induction of apoptotic and autophagic cell death by targeting survivin in head neck squamous cell carcinomaThe survivin suppressant YM155 reverses doxorubicin resistance in osteosarcoma.Targeting survivin using a combination of miR‑494 and survivin shRNA has synergistic effects on the suppression of prostate cancer growthInhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644: an aminobisphosphonate derivative.Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumors.NF-κB suppresses apoptosis and promotes bladder cancer cell proliferation by upregulating survivin expression in vitro and in vivo.Preclinical assesement of survivin and XIAP as prognostic biomarkers and therapeutic targets in gastroenteropancreatic neuroendocrine neoplasia.Manipulating the apoptotic pathway: potential therapeutics for cancer patients.Sepantronium is a DNA damaging agent that synergizes with PLK1 inhibitor volasertib.The role of clusterin in prostate cancer: treatment resistance and potential as a therapeutic target.Both IGF1R and INSR Knockdown Exert Antitumorigenic Effects in Prostate Cancer In Vitro and In Vivo.Putative tumor suppression function of SIRT6 in endometrial cancer.Antitumor effect of YM155, a novel small-molecule survivin suppressant, via mitochondrial apoptosis in human MFH/UPS.BIRC5/Survivin as a target for glycolysis inhibition in high-stage neuroblastoma.Dual inhibition of survivin and MAOA synergistically impairs growth of PTEN-negative prostate cancer.miR-542-3p exerts tumor suppressive functions in neuroblastoma by downregulating Survivin.Formulation design and evaluation of liposomal sepantronium bromide (YM155), a small-molecule survivin suppressant, based on pharmacokinetic modeling and simulation.Survivin inhibition via EZN-3042 in canine lymphoma and osteosarcoma.Harnessing Solute Carrier Transporters for Precision Oncology.Renal uptake of the antiapoptotic protein survivin is mediated by megalin at the apical membrane of the proximal tubule.
P2860
Q28483886-337C32EA-2385-4C29-9F23-524A2805DDB9Q28485864-45032685-D3E0-4A24-B2E5-E75703022277Q33764288-4D836D7A-D7CE-408F-95F8-251F82FBAD96Q33810310-7E3BC02F-56AD-4C5D-AF47-850BFCD97E28Q34079347-E5592EA6-C014-4984-AAAC-02E37D3C3BA2Q34273814-F3CE5794-F5AC-44BF-B283-31097C960650Q34766411-59237B28-B7FF-412E-A57E-947B4EE06F56Q34786411-A4F360A4-35FF-47E2-AEDA-A1DD5A286C60Q34795766-35B4E0FE-594E-44F9-8BED-9350FED68F8BQ34991312-4F109887-A951-4B56-8DC2-2E06BC86A900Q35048722-47C24421-5104-433A-A2B6-1C1153FAEFBFQ35049080-1388EB1D-DFCC-480B-95BC-68DA6F229114Q35205627-7A011036-4FB2-42EF-AA01-DC0AEF127B57Q35603263-31EED042-9F3A-4DC7-AC79-D5BF22D2B7D1Q35914683-DDA84E4A-4716-471C-9626-D0ADBA16760AQ35999255-F901A8CF-35DE-4C2D-8393-94CF806C13E8Q36070338-C3FF6E19-2EC1-4950-96DE-F4020BD92DF9Q36073279-798B61A6-FD91-4040-AAEC-22ECD3B5FC76Q36079787-A427333D-63B8-43EC-876B-25AC4070800DQ36194681-EBC6E460-137C-4512-A670-96479CD4F1F2Q36346978-74011D55-53E6-4A14-B0AD-48035C82AE52Q36411703-C87CB334-0073-4B43-B199-CE16B270BAA6Q36520194-EF7F6DDB-AD03-4FAA-A27B-E3930A5FF9A5Q37317305-166AD5F8-F8CA-4542-A9A4-31CB8D3F0605Q37598765-4188B109-FB60-42D4-B90B-259727C66D35Q37615242-1C5C0B62-A076-400B-A4BD-03442788D52EQ37702716-7A9B749B-9F36-437D-918C-9F3E28B4AF55Q38115574-BD33AFA5-941A-4074-8152-4804F699AE9FQ38366458-86255500-77CA-48F9-AEEA-D62B3AAEDA52Q38575004-48655A8A-E324-4933-B0B6-2F25E8C42800Q38829200-2509A157-51C7-4F2E-895D-66BE93C858A4Q38852078-F51D0ECB-0993-4BB3-9E54-A28F44C89681Q38853955-B8BA0897-E422-4474-B3F0-49165E26182FQ38856274-9F731FF4-C65F-4BBD-B7E4-2275388D83A8Q38860787-742B4A1A-DA73-4DA7-AF48-304185D4FA53Q38973284-EE21BACD-70D0-42AD-ABE6-072B5C0BECBBQ38974596-176E5EA3-E506-4431-80E4-0A7129860598Q38985503-0CBA3FFD-8650-4C24-BB70-FDDAED9687C2Q39204754-BE76E58B-E9D6-4E13-AE61-258AA840B38BQ41412746-4D61B75B-D0F4-4FD0-BA77-ED598D6CEB95
P2860
A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
A phase II study of YM155, a n ...... ne-pretreated prostate cancer.
@en
type
label
A phase II study of YM155, a n ...... ne-pretreated prostate cancer.
@en
prefLabel
A phase II study of YM155, a n ...... ne-pretreated prostate cancer.
@en
P2093
P2860
P356
P1433
P1476
A phase II study of YM155, a n ...... ne-pretreated prostate cancer.
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDR353
P577
2011-08-22T00:00:00Z